Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated. Copyright 2024 NPR The biggest portion of Boise ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
The Broadway icon said he’s a “great believer” in the weight-loss medication, which helped him after he weighed 310 lbs.